Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020
Presentation Title: | Recombinant nanoparticle COVID-19 vaccine: Platform technology for Emerging Infectious Diseases (EID) |
Time: |
For more information on the
About NVX-CoV2373
NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In the Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a Phase 3 trial in the
About Novavax
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
Investors
ir@novavax.com
240-268-2022
Media
Brandzone/KOGS Communication
kaplan@kogspr.com
617-974-8659
Source: Novavax, Inc.